Avidity Biosciences Stock Performance
| RNA Stock | USD 43.03 0.30 0.69% |
Avidity Biosciences has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.75, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Avidity Biosciences will likely underperform. Avidity Biosciences right now shows a risk of 4.15%. Please confirm Avidity Biosciences sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Avidity Biosciences will be following its price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Avidity Biosciences are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Avidity Biosciences may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Actual Historical Performance (%)
One Day Return (0.69) | Five Day Return (1.42) | Year To Date Return 369.76 | Ten Year Return 50.98 | All Time Return 50.98 |
1 | Acquisition by Arthur Levin of 22500 shares of Avidity Biosciences subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 5000 shares by Arthur Levin of Avidity Biosciences at 1.24 subject to Rule 16b-3 | 09/19/2024 |
3 | RNAConnect Announces New Distribution Agreements in Europe and Asia for its Groundbreaking RNA Analysis Products | 09/24/2024 |
4 | Disposition of 25000 shares by Teresa McCarthy of Avidity Biosciences at 48.5204 subject to Rule 16b-3 | 10/16/2024 |
5 | Avidity Biosciences, Inc. Insider Teresa Mccarthy Sells 25,000 Shares of Stock | 10/18/2024 |
6 | Disposition of 65182 shares by Michael MacLean of Avidity Biosciences at 8.82 subject to Rule 16b-3 | 11/06/2024 |
7 | Avidity Biosciences CFO sells 4.8 million in stock | 11/08/2024 |
8 | Avidity Biosciences SWOT analysis RNA stock poised for growth in precision cardiology | 11/12/2024 |
9 | Biotech Stock Roundup NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data | 11/14/2024 |
10 | Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response ... | 11/15/2024 |
11 | Disposition of 25000 shares by Teresa McCarthy of Avidity Biosciences at 14.22 subject to Rule 16b-3 | 11/18/2024 |
12 | COVID-19 virus could attack cancer cells and shrink tumors, new study suggests | 11/19/2024 |
13 | Avidity Biosciences, Inc. Insider Teresa Mccarthy Sells 25,000 Shares | 11/21/2024 |
14 | RNAs SWOT analysis promising pipeline drives biotech stock potential | 11/25/2024 |
15 | Advantage Alpha Capital Partners LP Invests 471,000 in Avidity Biosciences, Inc. | 11/27/2024 |
| Begin Period Cash Flow | 340.6 M |
Avidity |
Avidity Biosciences Relative Risk vs. Return Landscape
If you would invest 4,099 in Avidity Biosciences on September 2, 2024 and sell it today you would earn a total of 204.00 from holding Avidity Biosciences or generate 4.98% return on investment over 90 days. Avidity Biosciences is generating 0.1619% of daily returns assuming volatility of 4.1475% on return distribution over 90 days investment horizon. In other words, 36% of stocks are less volatile than Avidity, and above 97% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Avidity Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avidity Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avidity Biosciences, and traders can use it to determine the average amount a Avidity Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RNA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.15 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.16 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Avidity Biosciences is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avidity Biosciences by adding it to a well-diversified portfolio.
Avidity Biosciences Fundamentals Growth
Avidity Stock prices reflect investors' perceptions of the future prospects and financial health of Avidity Biosciences, and Avidity Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avidity Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (42.01) % | ||||
| Current Valuation | 3.55 B | ||||
| Shares Outstanding | 119.31 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 3.41 X | ||||
| Price To Sales | 510.99 X | ||||
| Revenue | 9.56 M | ||||
| Gross Profit | (141.18 M) | ||||
| EBITDA | (233.5 M) | ||||
| Net Income | (212.22 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 9.85 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.64 X | ||||
| Cash Flow From Operations | (119.06 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Market Capitalization | 5.17 B | ||||
| Total Asset | 628.55 M | ||||
| Retained Earnings | (570.76 M) | ||||
| Working Capital | 530.63 M | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
About Avidity Biosciences Performance
By analyzing Avidity Biosciences' fundamental ratios, stakeholders can gain valuable insights into Avidity Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avidity Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avidity Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.35) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.34) | (0.35) | |
| Return On Equity | (0.42) | (0.40) |
Things to note about Avidity Biosciences performance evaluation
Checking the ongoing alerts about Avidity Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avidity Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avidity Biosciences had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 9.56 M. Reported Net Loss for the year was (212.22 M) with loss before taxes, overhead, and interest of (141.18 M). | |
| Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Advantage Alpha Capital Partners LP Invests 471,000 in Avidity Biosciences, Inc. |
- Analyzing Avidity Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avidity Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Avidity Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avidity Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avidity Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avidity Biosciences' stock. These opinions can provide insight into Avidity Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |